NCT05824728View on ClinicalTrials.gov

Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 28, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Parkinson Disease Psychosis
Interventions
DRUG

AGB101

low-dose levetiracetam, 220 mg, extended release tablet

Trial Locations (1)

21287

RECRUITING

Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

AgeneBio
All Listed Sponsors
collaborator

AgeneBio

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT05824728 - Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis | Biotech Hunter | Biotech Hunter